Immunomodulatory effects of anti-angiogenic drugs. - Wikidata - wikimedia - TriplyDB

Immunomodulatory effects of anti-angiogenic drugs.

Immunomodulatory effects of anti-angiogenic drugs.

http://www.wikidata.org/entity/Q37847051

about

Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials Optimizing dendritic cell-based approaches for cancer immunotherapy Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.Improved angiostatic activity of dasatinib by modulation with hydrophobic chains The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Global survey of the immunomodulatory potential of common drugs.Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.Nivolumab in renal cell carcinoma: latest evidence and clinical potential.The potential role of sunitinib targeting melanomas.The targeting of immunosuppressive mechanisms in hematological malignancies.PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells.Strong emerging rationale for combining oncogene-targeted agents with immunotherapy.Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy.Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.Functional characterization of Foxp3-specific spontaneous immune responses.Immunomodulation in hepatocellular cancer.Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.Synergizing Engineered Immunotherapy with Molecularly Targeted Cancer Treatment Immune suppression and evasion in patients with head and neck cancer Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma

P2860

Q26822432-333917A9-6612-4176-85EB-90327FA0F749 Q34637535-83E71677-DC48-45CD-B528-D271DC83B31D Q34653776-E4D9C097-7ABF-414C-85AF-0E5F8A30ABD2 Q35043102-42B851A8-2FF7-4368-8B9D-3F643608158A Q35178869-48864AA5-1347-43B9-95BC-1F83055476AF Q35898395-9AA6C8C1-679F-4A00-A27F-E19E38D5EE3C Q36286833-90C4BA0F-EE30-467E-88DD-9DFDC84E0872 Q36355056-F2623CDE-8F5E-4CED-AE54-2943D2A54C5E Q36378963-78C0F438-57EF-43B6-9772-D7461E4A0A85 Q36462972-77BECA78-0744-408A-9143-C9639833E79C Q36478715-AA6D3F31-A83F-4578-80CA-7E16C558DF2C Q37698611-A716B86E-3848-4187-BF7D-66E1D9358E8B Q38139560-13300587-2922-4C34-A248-AAD0B9D5C0F2 Q38201231-60B33198-ABB4-4E5B-9F7B-C62DFE936949 Q38835020-DC2812DF-6727-41EE-9873-9BD3DF6C96C5 Q42115204-F6BCBA5B-C420-4A55-AF5D-6A526285072D Q46859831-F334BFCD-9846-4D24-A90E-D2BD941E38DB Q47221521-9B5629ED-336A-4B0C-9505-2B6F60902379 Q48153977-E666C179-3248-4A98-A39D-E483090DB298 Q50868528-5F330F3D-65AB-4F86-A4BD-8CFEC487D154 Q52346985-44799BBB-EB21-4A03-B076-BF0E1BCCA366 Q55075934-C9061F87-47CC-44CE-96D6-A0AA664DD5B7 Q56970013-41D784CA-491F-435A-B20C-16F7ABFFF146 Q58289735-45435B54-9A2B-43AA-9080-83A0B104D356 Q58733930-ECD6493D-9BF7-4317-BC2D-2E91D3B63E1A

P2860

Immunomodulatory effects of anti-angiogenic drugs.

http://www.wikidata.org/entity/Q37847051

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunomodulatory effects of anti-angiogenic drugs.

@en

Immunomodulatory effects of anti-angiogenic drugs.

@nl

type

label

Immunomodulatory effects of anti-angiogenic drugs.

@en

Immunomodulatory effects of anti-angiogenic drugs.

@nl

prefLabel

Immunomodulatory effects of anti-angiogenic drugs.

@en

Immunomodulatory effects of anti-angiogenic drugs.

@nl

P1433

Q37847051-82F8CB95-C9C9-4578-A65E-1ADFD0EF3300

P1476

Q37847051-D1689FE8-C471-4B08-A5F5-D0D602D0A8D8

P2093

Q37847051-12E2718B-95C4-41B7-8DB7-664CB5D2F8FE

Q37847051-4F8A99F7-7996-4561-9397-7C142A2B2E0F

Q37847051-4FCF2FC9-3D63-4EE5-A8C8-C2ECFFDAE80C

Q37847051-9108C5C7-6051-4C51-A6D0-B8A2E2AFC066

Q37847051-B12567A6-44BD-4F0D-964E-77FB89E0B522

P2860

Q37847051-01551140-BFF4-4F01-B25E-7C21E387592B

Q37847051-01902649-ED8B-4631-9B0C-0EFC2143B3AF

Q37847051-083AC0E6-050B-4086-B24B-ED515C2B209C

Q37847051-0F897C7D-E790-4E1F-9EF4-16517CE36E35

Q37847051-13CF6C56-54C5-4B3A-A3C2-810A9B0BCF7E

Q37847051-184F0A2E-5BC8-432E-B76C-52C00F19D57D

Q37847051-1C72F90C-AD25-4E38-9414-88017346418C

Q37847051-21089193-6E95-4688-BEA7-C253773D76CE

Q37847051-29F298F1-CA41-43BB-8373-6D62028881DE

Q37847051-2D547A62-FD42-4298-90E9-A32D591A394D

P2888

Q37847051-84F47001-8160-4BB1-9F76-6A3A5380A778

P304

Q37847051-15114642-3C89-477E-9FBB-557D4C133DAB

P31

Q37847051-2DF671B6-5464-4BB5-93EA-FAA615B177CA

P356

Q37847051-1591D330-5F71-4594-8FC2-9A8F1FEE0676

P433

Q37847051-CAF41C2A-5C0A-42F8-A86E-DE93C27C8504

P478

Q37847051-12B85220-64F0-45DA-B94A-642F32E892FA

P577

Q37847051-2A719EAB-1ACE-48E0-9689-83F0B6F94CD5

P6179

Q37847051-1DE624E3-B266-462A-BEA7-B41B1CD6E4DD

P698

Q37847051-3B520890-611D-44B8-A9F0-168ABBA5627F

P356

P1433

P1476

Immunomodulatory effects of anti-angiogenic drugs.

@en

P2093

A Bringmann

http://www.w3.org/2001/XMLSchema#string

A Heine

http://www.w3.org/2001/XMLSchema#string

P Brossart

http://www.w3.org/2001/XMLSchema#string

S A E Held

http://www.w3.org/2001/XMLSchema#string

T A W Holderried

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of nilotinib on regulatory T cells: the dose matters

The proteasome inhibitor bortezomib enhances the susceptibility to viral infection

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.

Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.

Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

The proteasome: a suitable antineoplastic target.

P2888

P304

899-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2011.24

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019283501

http://www.w3.org/2001/XMLSchema#string

P698

21350557

http://www.w3.org/2001/XMLSchema#string